Program
elraglusib
Also written as “9-ING-41” and “Elraglusib Oral Tablets”.
Its studies are mostly in Neoplasms · Primary Myelofibrosis · Salivary Gland Neoplasms, led by Actuate Therapeutics.
Furthest: phase 2, since Sep 15, 20185 company-led studies, 2 open or runningNext primary completion: Jul 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Actuate Therapeutics | 52 open or running | phase 2since Sep 15, 2018 | Sep 15, 2018 | Jul 2029phase 2 · NCT07714395 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 15, 2018First study: phase 2 study in NeoplasmsFirst studyNCT03678883 · 350 enrolled · United States, Belgium, Canada and more
- Jan 2, 2020Phase 2 study in Primary MyelofibrosisNCT04218071 · 17 enrolled · United States
- Jan 20, 2020Phase 1 study in NeoplasmsNCT04239092 · 40 enrolled · United States
- Apr 2, 2021Phase 2 study in Salivary Gland NeoplasmsNCT04832438 · United States
- Jun 19, 2026Phase 2 study in Advanced Malignant Solid TumorNCT07714395 · 100 planned
Ahead
- Jul 2029Primary completion: phase 2 study in Advanced Malignant Solid TumorNCT07714395
TargetBeta
GSK3B →read by rule
“Glycogen synthase kinase-3 beta inhibitor”ChEMBL 37, by rule
Other programs on GSK3B
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lithium Carbonaterule | Merck | phase 3 | 5 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07714395Advanced Malignant Solid Tumor | 2 | Not yet recruiting | Jul 2029 | 100 |
| NCT04832438Salivary Gland Neoplasms · United States | 2 | Withdrawn | Jun 18, 2033 | 0 |
| NCT04239092Neoplasms · United States | 1 | Terminated | Jul 7, 2025 | 40 |
| NCT04218071Primary Myelofibrosis · United States | 2 | Completed | Oct 13, 2022 | 17 |
| NCT03678883Neoplasms · United States, Belgium, Canada and more | 2 | Active, not recruiting | Jun 2026 | 350 |
How it is read
Names in the registry
- “9-ING-41”, 4 entries
- “Elraglusib Oral Tablets”, 1 entry
Conditions, from the studies’ own filings
- Neoplasms, 2 studies
- Primary Myelofibrosis, 1 study
- Salivary Gland Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.